Dr. Chao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
525 E 68th St
New York, NY 10065Phone+1 212-746-5454- Is this information wrong?
Summary
- Dr. Bo Chao is an oncologist in New York, NY and is affiliated with NewYork-Presbyterian/Weill Cornell. He received his medical degree from University of Minnesota Medical School and has been in practice 19 years. He also speaks multiple languages, including Chinese (Mandarin). He specializes in thoracic cancer and is experienced in thoracic oncology and lung neoplasms.
Education & Training
- University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2009 - 2011
- Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2005 - 2008
- University of Minnesota Medical SchoolClass of 2005
Certifications & Licensure
- NY State Medical License 2017 - 2026
- OH State Medical License 2012 - 2019
- WI State Medical License Active through 2013
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Start of enrollment: 2015 May 06
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29
- A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Start of enrollment: 2016 Oct 24
- Join now to see all
Publications & Presentations
PubMed
- Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stagefusion-positive non-small cell lung cancer.Jonathan W Goldman, Lynette M Sholl, Sanja Dacic, Michael C Fishbein, Yonina R Murciano-Goroff, Ravi Rajaram, Sylwia Szymczak, Anna M Szpurka, Bo H Chao, Alexander Drilon> ;Frontiers in Oncology. 2023 Jan 1
- 8 citationsLIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIAfusion-positive non-small-cell lung cancer.Masahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, Melissa L Johnson, Luis Paz-Ares, James Chih-Hsin Yang, Benjamin Besse, Weiji Su, Bo H Chao, Alexander Drilon> ;Future Oncology. 2022 Sep 1
- 30 citationsPhase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.Roy S. Herbst, Hendrik Tobias Arkenau, Johanna C. Bendell, Edward Arrowsmith, Martin Wermke, Andres O. Soriano, Nicolas Penel, Rafael Santana-Davila, Helge Bischoff, I...> ;Journal of Thoracic Oncology. 2021 Feb 1
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin)
Industry Relationships
- Senior Vice President, Puma Biotechnology2023 - Present
- Executive Medical Director, Eli Lilly and Company2015 - 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: